Skip to main content

Table 1 Comparison of demographics, clinical and laboratory data, primary pulmonary function parameters, and ILD subtypes in patients with MDA5+DM between the survival and non-survival groups

From: Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody

 

Non-survival group (N = 32)

Survival group (N = 94)

P-value

Female, no. (%)

14 (43.8)

64 (68.1)

0.014

Age at onset, years, median [IQR]

59 [55, 56]

48 [39, 57]

< 0.001

Diagnosis time, months, median [IQR]

1.0 [1.0, 3.0]

2.0 [1.0, 5.0]

0.036

Survival time, months, median [IQR]

3.6 [1.7, 7.2]

30.3 [15.0, 46.3]

< 0.001

Cause of death, no. (%)

 Respiratory failure

30 (93.8)

–

–

 Gastrointestinal hemorrhage

1 (3.1)

–

–

 Unknown

1 (3.1)

–

–

Laboratory data, median [IQR]

 ALT, U/L

71 [30, 133]

44 [24, 88]

0.069

 AST, U/L

76 [48, 153]

46 [29, 87]

0.008

 LDH, U/L

372 [284, 478]

301 [237, 368]

0.008

 CK, U/L

85 [43, 276]

60 [36, 103]

0.079

 Creatinine, μmol/L

56 [41, 60]

51 [41, 60]

0.385

 Ferritin, ng/mL

1301 [523, 1500]

532 [241, 1215]

0.003

 CRP, mg/L

14 [6, 25]

6 [3, 14]

0.002

 ESR, mm/h

38 [28, 69]

28 [19, 47]

0.011

 Total lymphocyte count, /µL

605 [390, 785]

745 [500, 1198]

0.030

 CD3+T lymphocyte count, /µL

362 [254, 527]

454 [292, 759]

0.025

 CD4+T lymphocyte count, /µL

249 [118, 385]

249 [162, 444]

0.241

 CD8+T lymphocyte count, /µL

119 [66, 150]

145 [83, 253]

0.029

Clinical characteristics, no. (%)

 Myodynia

10 (31.3)

27 (28.7)

0.786

 Muscle weakness

9 (28.1)

26 (27.7)

0.960

 Heliotropic rash

19 (59.4)

57 (60.6)

0.900

 V sign

12 (37.5)

42 (44.7)

0.478

 Shawl sign

9 (28.1)

23 (24.5)

0.681

 Gottron’s sign

25 (78.1)

75 (79.8)

0.841

 Skin ulcer

5 (15.6)

9 (9.6)

0.347

 Mechanics hand

10 (31.3)

33 (35.1)

0.691

 Periungual erythema

8 (25.0)

23 (24.5)

0.952

 Dysphagia

3 (9.4)

7 (7.4)

1.000

 Malignancy

3 (9.4)

3 (9.4)

0.348

 Overlap CTDs

0 (0)

7 (7.4)

0.190

Pulmonary function

 FVC, % pred, mean ± SD

66 ± 21a

75 ± 19b

0.091

 FEV1, % pred, mean ± SD

66 ± 19a

74 ± 18b

0.093

 DLco, % pred, mean ± SD

49 ± 33c

56 ± 17d

0.489

 TLC, % pred, median [IQR]

67 [56, 78]c

75 [64, 86]d

0.213

ILD subtypes, no. (%)

 RP-ILD

29 (90.6)

9 (9.6)

< 0.001

 C-ILD

2 (6.3)

79 (84.0)

< 0.001

 Non-ILD

1 (3.2)

6 (6.4)

0.804

  1. Bold text highlights the significance
  2. MDA5+DM Anti-MDA5 dermatomyositis, ALT Alanine transaminase, AST Aspartate transaminase, LDH Lactate dehydrogenase, CK Creatine kinase, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, CTDs Connective tissue diseases, FVC forced vital capacity, FEV1 Forced expiratory volume in 1 s, Dlco, diffusing capacity of the lungs for carbon monoxide, TLC Total lung capacity, % pred Percent predicted values, RP-ILD Rapidly progressive interstitial lung disease, C-ILD Chronic interstitial lung disease
  3. aData available for 17 patients
  4. bData available for 62 patients
  5. cData available for 14 patients
  6. dData available for 61 patients
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us